On April 23, 2026, the FDA approved Otarmeni (lunsotogene parvec-cwha), Regeneron’s gene therapy for a rare inherited form of hearing loss, just 61 days after the biologics application was filed. It was the sixth product cleared under the Commissioner’s National Priority Voucher (CNPV) pilot, and the first gene therapy. The program, launched in June 2025, compresses review of eligible drugs and biologics from the standard 10 to 12 months down to one or two. By May 2026 the FDA had granted seven CNPV approvals, and the voucher pool had grown from 15 early in the year to 18.
For self-funded health plans, the number that changes is not the sticker price of any single therapy. It is the count of catastrophic single-dose claims that can land in one plan year.
Who it affects
Self-insured employers and public entities carrying medical risk above a specific deductible, plus the aggregate stop-loss carriers that reinsure them. Mid-size self-funded plans, roughly 500 to 5,000 covered lives, are the most exposed. A plan that size may see zero gene-therapy claims for years, then two in a twelve-month window. That is the shape of loss that specific and aggregate stop-loss are least equipped to absorb.
The reserve mechanism: frequency, not severity
Most coverage of gene therapy fixates on severity, the $2 million to $4 million cost of a single dose. That framing misreads the exposure. Severity is already priced into specific stop-loss attachment points and laser terms. What the CNPV acceleration changes is the expected number of those claims reaching a plan in a given year, and frequency is the variable that breaks aggregate stop-loss math.
Aggregate stop-loss caps a plan’s total claims for the year. The margin between expected claims and the aggregate attachment point is set on a frequency assumption for high-cost events. Feed a faster approval pipeline into that assumption and the assumption is stale before the plan year starts. Two $3 million claims against a plan whose aggregate corridor was built for at most one is a direct breach, and the plan absorbs the gap until the aggregate layer responds. See our companion analysis of gene therapy and aggregate stop-loss for how that corridor is constructed.
“Free” does not zero out the reserve. Regeneron is providing Otarmeni at no acquisition cost in the U.S., but administration, hospitalization, monitoring, and downstream care still flow through the plan. The next CNPV gene therapy may carry a full list price. Reserving to the acquisition cost of the one free product is a planning error.
Where this shows up in your reserves
On the stop-loss reconciliation, watch the frequency assumption behind the aggregate attachment factor, not the specific deductible line. On the plan’s expected claim ratio, the catastrophic-claim load is the row that a faster pipeline erodes first. The credibility problem is real: a single plan almost never has enough $1 million-plus claims to price frequency on its own, so the assumption leans on carrier and manual data that lag the CNPV pipeline by a renewal cycle or more. Our self-funded health IBNR primer walks through where the catastrophic load sits in the accrual.
What this means for your next review
Ask your actuary and stop-loss broker for the explicit frequency assumption for $1 million-plus single-dose claims sitting behind your current aggregate attachment, and how many such claims in one year would breach it. If the answer is “one,” you are underwriting a pipeline that now produces gene-therapy approvals in 61 days.
Decision-maker checklist
- Confirm the frequency assumption behind your aggregate stop-loss attachment, and stress it for two catastrophic claims in one plan year.
- Ask your broker how gene-therapy specific terms, lasers, and aggregating specific deductibles change at 2027 renewal.
- Verify you are reserving administration and downstream cost on therapies that are free at acquisition.
- Track the next batch of CNPV approvals as a leading indicator of catastrophic-claim frequency, not just severity.
Sources
- FDA: First-Ever Gene Therapy for Genetic Hearing Loss Under the National Priority Voucher Program
- FDA: Commissioner’s National Priority Voucher (CNPV) Pilot Program
- Regeneron: Otarmeni Approved by FDA; to Be Provided Free in the U.S.
- BioPharma Dive: FDA approves Regeneron’s hearing loss gene therapy